AEROVENT

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

اشتر الآن

العنصر النشط:

IPRATROPIUM BROMIDE

متاح من:

BOEHRINGER INGELHEIM ISRAEL LTD.

ATC رمز:

R03BB01

الشكل الصيدلاني:

RESPIRATOR SOLUTION

تركيب:

IPRATROPIUM BROMIDE 0.25 MG/ML

طريقة التعاطي:

INHALATION

نوع الوصفة الطبية :

Required

المصنعة من قبل:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

المجموعة العلاجية:

IPRATROPIUM BROMIDE

المجال العلاجي:

IPRATROPIUM BROMIDE

الخصائص العلاجية:

For the relief of symptoms of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema . Aerovent respirator solution is of particular benefit in relieving acute bronchospasm when used concomitantly with inhaled beta agonists.

تاريخ الترخيص:

2012-01-31

نشرة المعلومات

                                Aerovent
Proposed patient information
Boehringer Ingelheim
November 2020
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) -
1986
This medicine is dispensed with a doctor’s prescription only
AEROVENT
®
SOLUTION FOR INHALATION
EVERY 1 ML (20 DROPS) CONTAINS:
IPRATROPIUM BROMIDE 0.25 MG
Inactive ingredients and allergens: see section 2 under ‘Important
information about
some of this medicine’s ingredients’, and section 6 ‘Additional
information'.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet
contains concise information about this medicine. If you have any
further questions,
consult your doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to
others. It may harm
them, even if it seems to you that their medical condition is similar
to yours.
1. WHAT IS THIS MEDICINE INTENDED FOR?
Relieving symptoms of reversible bronchospasm associated with asthma,
chronic
bronchitis, and emphysema.
AEROVENT is particularly effective in relieving acute bronchial
constriction when
given together with inhaled beta agonists.
THERAPEUTIC GROUP: anticholinergic.
2.
BEFORE USING THIS MEDICINE
DO NOT USE THIS MEDICINE IF:
•
You are sensitive (allergic) to the active ingredient ipratropium
bromide, to
atropine or atropine derivatives (anticholinergic active substances
with
similar structure) or to any of the other ingredients in this medicine
(listed
in section 6).
•
You are pregnant (particularly during the first three months) or are
breastfeeding, unless your doctor has recommended this treatment after
weighing the risk and benefit.
SPECIAL WARNINGS ABOUT USING THIS MEDICINE
Consult your doctor or pharmacist before using this medicine.
TALK TO YOUR DOCTOR OR PHARMACIST BEFORE USING AEROVENT IF:
•
Care must be taken to ensure that the solution or the mist from the
nebulizer
does not get into the eyes. ATROVENT should be used with special care
in
patients with a tendency to narrow-angle glaucoma. If the medicine
accidentally ge
                                
                                اقرأ الوثيقة كاملة
                                
                            

خصائص المنتج

                                Aerovent
Proposed prescribing information
Boehringer Ingelheim
January 2022
AEROVENT
IPRATROPIUM BROMIDE 0.25 MG/ML
Respirator solution for inhalation
1.
NAME OF THE MEDICINAL PRODUCT
AEROVENT
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml (20 drops) contains:
Ipratropium bromide 0.25 mg
Excipient with known effect: 0.10 mg benzalkonium chloride/ml
(corresponds to 10 µg per actuation),
see section 4.4.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
RESPIRATOR SOLUTION
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the relief of symptoms of reversible bronchospasm associated with
asthma, chronic bronchitis
and emphysema.
Aerovent respirator solution is of particular benefit in relieving
acute bronchospasm when used
concomitantly with inhaled beta agonists.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The dosage should be adapted to the individual requirements of the
patient; patients should also be kept
under medical supervision during treatment. It is advisable not to
greatly exceed the recommended daily
dose during both acute and maintenance treatment.
If therapy does not produce a significant improvement or if the
patient's condition worsens, medical
advice must be sought in order to determine a new regimen of therapy.
In the case of acute or rapidly
worsening dyspnea, a doctor should be consulted immediately.
Note: Aerovent and disodium cromoglycate inhalation solutions should
not be simultaneously
administered in the same nebulizer as precipitation may occur.
Aerovent
Proposed prescribing information
Boehringer Ingelheim
January 2022
Aerovent Respirator Solution may be administered from an intermittent
positive pressure ventilator or
from suitable nebulizers.
The following dosages are recommended:
ADULTS
0.1 - 0.5 mg (0.4 - 2.0 ml = 8-40 drops) up to 4 times daily.
CHILDREN
_6-12 Years_
: 0.25 mg (20 drops, i.e., 1 ml) 3 to 4 times daily.
_Children < 6 years of age:_
As only limited information is available for this age group, the
following dose schedule should only be
gi
                                
                                اقرأ الوثيقة كاملة
                                
                            

مستندات بلغات أخرى

نشرة المعلومات نشرة المعلومات العربية 09-12-2020
نشرة المعلومات نشرة المعلومات العبرية 06-01-2022

تنبيهات البحث المتعلقة بهذا المنتج

عرض محفوظات المستندات